Here’s why Mesoblast limited (ASX:MSB) and this ASX 200 share have more than doubled in value in 2020…
The post Why Mesoblast (ASX:MSB) and this ASX 200 share have doubled in value in 2020 appeared first on Motley Fool Australia. –
I think it is fair to say that it has been a year to forget for the S&P/ASX 200 Index (ASX: XJO).
Since the start of the year, the benchmark index has lost 13.5% of its value.
The good news is that not all shares on the index have dropped lower this year. In fact, a couple of shares are not only beating the market, they have more than doubled in value in 2020.
Here’s why they are on fire this year:
Afterpay Ltd (ASX: APT)
The Afterpay share price is the best performer on the ASX 200 in 2020 with a whopping 161% gain. Impressively, this is despite the buy now pay later provider’s shares trading 20% lower than their 52-week high.
The catalyst for this strong gain has been the rapid growth in customer and underlying sales numbers during the pandemic. This has been driven by an acceleration in the shift to online shopping and the growing popularity of the payment method with consumers and merchants. Also getting investors excited is its expansion plans. Afterpay recently revealed plans to enter the European market and also has its eyes on the Asian market.
Mesoblast limited (ASX: MSB)
The Mesoblast share price is up 141% since the start of the year. Investors have been buying this biotechnology company’s shares due to positive developments relating to its remestemcel-L product candidate. Remestemcel-L is being developed as a treatment for paediatric steroid-resistance acute graft versus host disease (paediatric SR-aGvHD).
In August the company had a meeting with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. FDA to discuss remestemcel-L as a potential treatment for paediatric SR-aGvHD. Pleasingly, after some initial doubts, the ODAC was supportive of remestemcel-L and gave it the thumbs up. While this doesn’t guarantee FDA approval, it’s a huge step forward. In addition to this, there is excitement around the company’s trials of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome. Phase 3 trials are currently underway in Australia and the United States.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- Correction or crash for ASX 200 shares?
- Is the Coles (ASX:COL) share price a buy after renewable energy deal?
- 2 stunning ASX growth shares to buy and hold
- 5 things to watch on the ASX 200 on Wednesday
- The next ASX stock to be rocked by board shakeup after Rio Tinto (ASX:RIO)
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.